Evidence map›Paper›PMID 32793495›Full record

ArticleFrontiers in oncology2020

Longitudinal Monitoring of

Ning Li, Udayan Guha, Chul Kim, Leah Ye, Jordan Cheng, Feng Li, David Chia, Fang Wei, David T W Wong

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.6field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. [Developments in Research on Salivary Biomarkers in the Diagnosis of Systemic Diseases].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2023
    Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Ning LiDepartment of Oral and Maxillofacial Surgery, Xiangya Hospital, Central South University, Changsha, China.
Udayan GuhaThoracic and Gastrointestinal Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, United States.
Chul KimThoracic and Gastrointestinal Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, United States.
Leah YeSchool of Dentistry, University of California, Los Angeles, Los Angeles, CA, United States.
Jordan ChengSchool of Dentistry, University of California, Los Angeles, Los Angeles, CA, United States.
Feng LiSchool of Dentistry, University of California, Los Angeles, Los Angeles, CA, United States.
David ChiaSchool of Dentistry, University of California, Los Angeles, Los Angeles, CA, United States.
Fang WeiSchool of Dentistry, University of California, Los Angeles, Los Angeles, CA, United States.
David T W WongSchool of Dentistry, University of California, Los Angeles, Los Angeles, CA, United States.
University of California, Los Angeles · USCenter for Cancer Research · USCentral South University · CNNational Cancer Institute · US

Funding

EFIRM Liquid Biopsy Research Laboratory: Early Lung Cancer AssessmentU01CA233370 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ABERLE, DENISE R., HSU, WILLIAM · 2018 to 2025
$8.0M
Clinical Utility of Salivary ExRNA Biomarkers for Gastric Cancer DetectionUH3TR000923 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WONG, DAVID T · 2015 to 2017
$2.7M
Advancing EFIRM-Liquid Biopsy (eLB) to a CLIA-Certified Laboratory Developed Test (eLB-LDT) for Detection of Actionable EGFR Mutations in NSCLC PatientsUH3CA206126 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHIA, DAVID S., SOO HOO, GUY · 2019 to 2021
$1.2M
Ultra-short circulating tumor DNA (uctDNA) for liquid biopsy of non-small cell lung cancerR21CA239052 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LI, FENG, WONG, DAVID T · 2019 to 2020
$373k
Advancing EFIRM-Liquid Biopsy (eLB) to a CLIA-Certified Laboratory Developed Test (eLB-LDT) for Detection of Actionable EGFR Mutations in NSCLC PatientsUH2CA206126 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHIA, DAVID S., DAS, KINGSHUK · 2017 to 2018
$368k
NCATS NIH HHS UH3 TR000923NCI NIH HHS R21 CA239052NCI NIH HHS U01 CA233370NCI NIH HHS UH2 CA206126NCI NIH HHS UH3 CA206126
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

acquired resistancegene mutationliquid biopsylocal ablative therapynon-small cell lung cancerosimertinib

Identifiers

PMID32793495
PMCPMC7393232
OpenAlexW3044149473

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.